{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:13:06Z","timestamp":1761808386074,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40256-020-00429-7","type":"journal-article","created":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T08:36:15Z","timestamp":1596270975000},"page":"413-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0424-4208","authenticated-orcid":false,"given":"Fabian","family":"Sanchis-Gomar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel P.","family":"Morin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carme","family":"Perez-Quilis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jari A.","family":"Laukkanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco V.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,1]]},"reference":[{"key":"429_CR1","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.7150\/ijbs.45498","volume":"16","author":"N Yang","year":"2020","unstructured":"Yang N, Shen HM. Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19. Int J Biol Sci. 2020;16:1724\u201331.","journal-title":"Int J Biol Sci"},{"key":"429_CR2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ijid.2020.02.018","volume":"93","author":"PI Andersen","year":"2020","unstructured":"Andersen PI, Ianevski A, Lysvand H, Vitkauskiene A, Oksenych V, Bjoras M, et al. Discovery and development of safe-in-man broad-spectrum antiviral agents. Int J Infect Dis. 2020;93:268\u201376.","journal-title":"Int J Infect Dis"},{"key":"429_CR3","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.20.255943","author":"O Kadioglu","year":"2020","unstructured":"Kadioglu O, Saeed M, Johannes Greten H, Efferth T. Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning. Bull World Health Organ. 2020. https:\/\/doi.org\/10.2471\/BLT.20.255943.","journal-title":"Bull World Health Organ."},{"key":"429_CR4","doi-asserted-by":"publisher","first-page":"e01","DOI":"10.15420\/usc.2020.14","volume":"14","author":"AS Rali","year":"2020","unstructured":"Rali AS, Sauer AJ. COVID-19 pandemic and cardiovascular disease. US Cardiol Rev. 2020;14:e01.","journal-title":"US Cardiol Rev"},{"key":"429_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00210-013-0865-0","volume":"386","author":"J Heijman","year":"2013","unstructured":"Heijman J, Dobrev D. Pleiotropic actions of amiodarone: still puzzling after half a century. Naunyn Schmiedebergs Arch Pharmacol. 2013;386:571\u20134.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"429_CR6","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1001\/jama.296.23.2839","volume":"296","author":"AK Gehi","year":"2006","unstructured":"Gehi AK, Mehta D, Gomes JA. Evaluation and management of patients after implantable cardioverter-defibrillator shock. JAMA. 2006;296:2839\u201347.","journal-title":"JAMA"},{"key":"429_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00210-013-0862-3","volume":"386","author":"B Polat","year":"2013","unstructured":"Polat B, Cadirci E, Halici Z, Bayir Y, Unal D, Bilgin BC, et al. The protective effect of amiodarone in lung tissue of cecal ligation and puncture-induced septic rats: a perspective from inflammatory cytokine release and oxidative stress. Naunyn Schmiedebergs Arch Pharmacol. 2013;386:635\u201343.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"429_CR8","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1161\/01.CIR.96.5.1386","volume":"96","author":"A Matsumori","year":"1997","unstructured":"Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S. Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure. Circulation. 1997;96:1386\u20139.","journal-title":"Circulation"},{"key":"429_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.04.019","author":"AW Wong","year":"2020","unstructured":"Wong AW, Fidler L, Marcoux V, Johannson KA, Assayag D, Fisher JH, et al. Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the COVID-19 pandemic. Chest. 2020. https:\/\/doi.org\/10.1016\/j.chest.2020.04.019.","journal-title":"Chest"},{"key":"429_CR10","doi-asserted-by":"publisher","first-page":"e008719","DOI":"10.1161\/CIRCEP.120.008719","volume":"13","author":"SM Kochav","year":"2020","unstructured":"Kochav SM, Coromilas E, Nalbandian A, Ranard LS, Gupta A, Chung MK, et al. Cardiac Arrhythmias in COVID-19 Infection. Circ Arrhythm Electrophysiol. 2020;13:e008719.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"429_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fcvm.2020.00085","volume":"7","author":"A Carpenter","year":"2020","unstructured":"Carpenter A, Chambers OJ, El Harchi A, Bond R, Hanington O, Harmer SC, et al. COVID-19 management and arrhythmia: risks and challenges for clinicians treating patients affected by SARS-CoV-2. Front Cardiovasc Med. 2020;7:85.","journal-title":"Front Cardiovasc Med"},{"key":"429_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/jac\/dkv305","volume":"71","author":"C Salata","year":"2016","unstructured":"Salata C, Munegato D, Piccoli E, Calistri A, Parolin C, Mirazimi A, et al. Amiodarone increases positive-strand RNA virus replication in vitro: implications for its use in patients with viral infections. J Antimicrob Chemother. 2016;71:280\u20131.","journal-title":"J Antimicrob Chemother"},{"key":"429_CR13","doi-asserted-by":"publisher","first-page":"ftv032","DOI":"10.1093\/femspd\/ftv032","volume":"73","author":"C Salata","year":"2015","unstructured":"Salata C, Baritussio A, Munegato D, Calistri A, Ha HR, Bigler L, et al. Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process. Pathog Dis. 2015;73:ftv032.","journal-title":"Pathog Dis"},{"key":"429_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1165\/rcmb.2007-0217OC","volume":"39","author":"K Stadler","year":"2008","unstructured":"Stadler K, Ha HR, Ciminale V, Spirli C, Saletti G, Schiavon M, et al. Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level. Am J Respir Cell Mol Biol. 2008;39:142\u20139.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"429_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/2047487320919233","author":"A Aimo","year":"2020","unstructured":"Aimo A, Baritussio A, Emdin M, Tascini C. Amiodarone as a possible therapy for coronavirus infection. Eur J Prev Cardiol. 2020. https:\/\/doi.org\/10.1177\/2047487320919233.","journal-title":"Eur J Prev Cardiol"},{"key":"429_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1160\/TH11-09-0650","volume":"107","author":"RT Megens","year":"2012","unstructured":"Megens RT, Vijayan S, Lievens D, Doring Y, van Zandvoort MA, Grommes J, et al. Presence of luminal neutrophil extracellular traps in atherosclerosis. Thromb Haemost. 2012;107:597\u20138.","journal-title":"Thromb Haemost"},{"key":"429_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.21037\/atm-20-3989","volume":"8","author":"G Lippi","year":"2020","unstructured":"Lippi G, Sanchis-Gomar F, Henry BM. COVID-19: unravelling the clinical progression of nature\u2019s virtually perfect biological weapon. Ann Transl Med. 2020;8:693.","journal-title":"Ann Transl Med"},{"key":"429_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1006\/cyto.2001.0996","volume":"17","author":"H Ito","year":"2002","unstructured":"Ito H, Ono K, Nishio R, Sasayama S, Matsumori A. Amiodarone inhibits interleukin 6 production and attenuates myocardial injury induced by viral myocarditis in mice. Cytokine. 2002;17:197\u2013202.","journal-title":"Cytokine"},{"key":"429_CR19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S0002-9149(98)00874-1","volume":"83","author":"H Oral","year":"1999","unstructured":"Oral H, Fisher SG, Fay WP, Singh SN, Fletcher RD, Morady F. Effects of amiodarone on tumor necrosis factor-alpha levels in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1999;83:388\u201391.","journal-title":"Am J Cardiol"},{"key":"429_CR20","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1253\/circj.CJ-08-0794","volume":"73","author":"Y Hirasawa","year":"2009","unstructured":"Hirasawa Y, Nakagomi A, Kobayashi Y, Katoh T, Mizuno K. Short-term amiodarone treatment attenuates the production of monocyte cytokines and chemokines by C-reactive protein and improves cardiac function in patients with idiopathic dilated cardiomyopathy and ventricular tachycardia. Circ J. 2009;73:639\u201346.","journal-title":"Circ J"},{"key":"429_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejphar.2007.03.046","volume":"566","author":"Z Halici","year":"2007","unstructured":"Halici Z, Dengiz GO, Odabasoglu F, Suleyman H, Cadirci E, Halici M. Amiodarone has anti-inflammatory and anti-oxidative properties: an experimental study in rats with carrageenan-induced paw edema. Eur J Pharmacol. 2007;566:215\u201321.","journal-title":"Eur J Pharmacol"},{"key":"429_CR22","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1161\/01.CIR.100.7.690","volume":"100","author":"T Ide","year":"1999","unstructured":"Ide T, Tsutsui H, Kinugawa S, Utsumi H, Takeshita A. Amiodarone protects cardiac myocytes against oxidative injury by its free radical scavenging action. Circulation. 1999;100:690\u20132.","journal-title":"Circulation"},{"key":"429_CR23","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1253\/circj.CJ-09-0038","volume":"73","author":"H Nakaya","year":"2009","unstructured":"Nakaya H. Does anti-inflammatory action of amiodarone explain the high efficacy in patients with heart failure? Circ J. 2009;73:622\u20133.","journal-title":"Circ J"},{"key":"429_CR24","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.02.20047050","author":"E Chorin","year":"2020","unstructured":"Chorin E, Dai M, Shulman E, Wadhwani L, Bar Cohen R, Barbhaiya C, et al. The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine\/azithromycin. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.04.02.20047050.","journal-title":"medRxiv."},{"key":"429_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-020-00401-5","author":"D Hamilton Sr","year":"2020","unstructured":"Hamilton D Sr, Nandkeolyar S, Lan H, Desai P, Evans J, Hauschild C, et al. Amiodarone: a comprehensive guide for clinicians. Am J Cardiovasc Drugs. 2020. https:\/\/doi.org\/10.1007\/s40256-020-00401-5.","journal-title":"Am J Cardiovasc Drugs."},{"key":"429_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jcrc.2011.10.009","volume":"27","author":"LV Karnatovskaia","year":"2012","unstructured":"Karnatovskaia LV, Festic E, Gajic O, Carter RE, Lee AS, Illness USC, et al. Prehospital amiodarone may increase the incidence of acute respiratory distress syndrome among patients at risk. J Crit Care. 2012;27:447\u201353.","journal-title":"J Crit Care"},{"issue":"7","key":"429_CR27","doi-asserted-by":"publisher","first-page":"e00819","DOI":"10.1128\/AAC.00819-20","volume":"64","author":"S Jeon","year":"2020","unstructured":"Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother. 2020;64(7):e00819\u2013e820. https:\/\/doi.org\/10.1128\/AAC.00819-20.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00429-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-020-00429-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00429-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T23:20:13Z","timestamp":1627773613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-020-00429-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,1]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["429"],"URL":"https:\/\/doi.org\/10.1007\/s40256-020-00429-7","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2020,8,1]]},"assertion":[{"value":"1 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Fabian Sanchis-Gomar, Carl J. Lavie, Daniel P. Morin, Carme Perez-Quilis, Jari A. Laukkanen, and Marco V. Perez declare they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}